AI Article Synopsis
- The study compared the effects of bevantolol and metoprolol in treating idiopathic dilated cardiomyopathy (DCM) in 41 patients.
- Both medications resulted in improved echocardiographic measurements and reduced levels of atrial and brain natriuretic peptides after 6 months of treatment.
- There were no significant differences in the efficacy between the two drugs, suggesting that bevantolol has similar benefits to metoprolol for cardiac function in DCM patients.
Article Abstract
This study was designed to compare the efficacy of bevantolol, a beta(1)-selective blocker with alpha-blockade and vasodilating activity, with that of metoprolol, a beta(1)-selective receptor blocker, for the treatment of idiopathic dilated cardiomyopathy (DCM). Forty-one patients with DCM were enrolled to receive either bevantolol or metoprolol in addition to the standard therapy for DCM. They were classified into two groups: 16 patients were treated with bevantolol and 25 were treated with metoprolol. Echocardiographic parameters and atrial and brain natriuretic peptides (ANP, BNP) were measured before treatment and after 6 months of treatment. Left ventricular dimension at end-diastole and end-systole was significantly lower and fractional shortening was significantly higher after treatment than before treatment in both groups. The plasma ANP and BNP levels were significantly decreased in both groups. Changes in all variables, except for systolic blood pressure, showed no significant differences between the two groups. In conclusion, bevantolol showed parallel beneficial effects to those of metoprolol on cardiac function and natriuretic peptides in patients with DCM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s003800200043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Natriuretic Peptides in Pericardial Fluid in Predicting Cardiovascular Disorders: A Systematic Review.
Cardiol Rev
October 2024
Division of Cardiac Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH.
Atrial and ventricular natriuretic peptides play an important role in the neurohormonal regulation of cardiac function. Plasma levels of these peptides may aid in the diagnosis and prognosis of different cardiac disorders, such as congestive heart failure, ischemic heart disease, and atrial fibrillation. However, the association between elevated pericardial fluid levels of natriuretic peptides and these clinical conditions has not been proven.
View Article and Find Full Text PDFDesign and rationale of the eLym™ System for Decompensation of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA-HF).
ESC Heart Fail
December 2024
Division of Cardiovascular Medicine, Ohio State University, Columbus, Ohio, USA.
Aims: The interstitial space is the major compartment in which the excess fluid is located, forming peripheral congestion in acute decompensated heart failure (ADHF). The lymphatic system is responsible for the constant drainage of the compartment. In ADHF, the inefficiency of this system causes extravascular fluid accumulation, underscoring the crucial role of lymphatic system failure in ADHF's pathophysiology.
View Article and Find Full Text PDFBaseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF.
ESC Heart Fail
December 2024
Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Aims: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of dapagliflozin on health status vary based on estimated glomerular filtration rate (eGFR).
View Article and Find Full Text PDFThe assessment of the relationship between the development of cardiovascular diseases and SCUBE-1 level in individuals exposed to loud noise.
Medicine (Baltimore)
December 2024
Harran University Faculty of Medicine, Department of Cardiology, Şanliurfa, Turkey.
Development of industry in the modern world, the number of individuals working in noisy environments is increasing with each passing day. Noise causes an increase in the incidence of cardioembolic events, yet the relevant underlying pathophysiology remains unclear. In this study, we aimed to investigate the relationship between signal peptide and complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor domain-containing protein-1 (SCUBE-1) in the pathophysiology of cardioembolic events in individuals exposed to noisy environments.
View Article and Find Full Text PDFAssociations of elevated cardiac biomarkers with hyperuricemia and mortality in US adults without prevalent cardiovascular disease.
Front Endocrinol (Lausanne)
December 2024
Department of Cardiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Background: NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin T (hs-troponin T), and high-sensitivity cardiac troponin I (hs-troponin I) have been widely recognized as significant cardiac biomarkers, and are increasingly being recommended for early risk identification in cardiovascular high-risk populations. The aim of our study was to evaluate the prevalence of elevated cardiac biomarkers (NT-proBNP, hs-troponin T, hs-troponin I) and their association with the risk of hyperuricemia in the general US adults without known cardiovascular disease. We further studied whether elevated cardiac biomarkers are associated with an increased risk of all-cause and cardiovascular mortality in individuals with or without hyperuricemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!